Oral Endocrine Therapies And Multi Asset Pipeline Will Reshape Rare Disease Treatment

Catalysts

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals focuses on developing and commercializing oral therapies for serious endocrine diseases, including acromegaly, carcinoid syndrome and congenital adrenal hyperplasia.

What are the underlying business or industry changes driving this perspective?

• The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.
• Growing focus on chronic symptom control and quality of life in rare endocrine diseases, supported by PALSONIFY’s label that highlights both biochemical and symptom control, can support physician preference and patient driven demand, which may help sustain prescription volumes and future earnings.
• The industry wide move toward outpatient and community based specialty care aligns with Crinetics’ early success in community endocrinology practices. Roughly 70% of early PALSONIFY prescriptions are coming from these settings, which can broaden prescriber reach and support a wider revenue base.
• Broadening use of targeted therapies in neuroendocrine tumors and adrenal disorders supports Crinetics’ multi asset pipeline, including paltusotine in carcinoid syndrome, Atumelnant in adult and pediatric CAH and the NDC platform, which together create several possible future revenue streams beyond PALSONIFY.
• Industry preference for companies with long cash runways and self funded development aligns with Crinetics’ cash balance of about US$1.1b and guidance to fund operations into 2029. This reduces near term financing risk and supports execution on programs aimed at improving margins and future earnings.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Crinetics Pharmaceuticals's revenue will grow by 566.4% annually over the next 3 years.
• Analysts are not forecasting that Crinetics Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Crinetics Pharmaceuticals's profit margin will increase from -27563.3% to the average US Pharmaceuticals industry of 20.9% in 3 years.
• If Crinetics Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $94.8 million (and earnings per share of $0.94) by about January 2029, up from $-423.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $109.3 million in earnings, and the most bearish expecting $-425.6 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 107.0x on those 2029 earnings, up from -10.8x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.6x.
• Analysts expect the number of shares outstanding to grow by 1.98% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• PALSONIFY is still in the very early stages of its commercial launch, and Q3 2025 results show that product revenue had not yet started while selling and R&D spending are already significant. If prescription growth settles at a lower level than management hopes, the mismatch between commercial expectations and actual uptake could pressure revenue and extend the period of losses.
• Crinetics is investing heavily in a broad late stage and early stage pipeline, including carcinoid syndrome, CAH, NDC oncology programs and a GLP related effort, and has already had to delay its Graves’ disease and ADPKD preclinical programs after tox findings. Further setbacks or slower progress in these long term programs could limit future product diversity and weigh on earnings and net margins.
• The company’s plan to expand acromegaly treatment relies on re engaging thousands of discontinued or lost to follow up patients and on improving diagnosis rates over time. However, rare disease care often moves slowly, and if awareness campaigns, pituitary center activation and community outreach do not materially change long run patient flows, the potential acromegaly market may remain smaller than management is planning around, capping revenue.
• Crinetics expects its current US$1.1b cash balance to fund operations into 2029 while it scales a field force, funds multiple Phase 3 trials and runs early oncology studies. If operating cash use does not moderate as expected or launch metrics underperform, the company may eventually need additional capital that could dilute shareholders and weigh on per share earnings.
• The long term thesis assumes durable payer support for PALSONIFY across commercial, Medicare and Medicaid, but rare disease therapies often face evolving prior authorization rules, step edits and competing lower cost options such as generics. If payers tighten access or reimbursement terms after initial enthusiasm, net pricing and volume could come under pressure, affecting revenue and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $82.43 for Crinetics Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $108.0, and the most bearish reporting a price target of just $45.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $454.3 million, earnings will come to $94.8 million, and it would be trading on a PE ratio of 107.0x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $48.18, the analyst price target of $82.43 is 41.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.